SCHEMBL4524846

SCHEMBL4524846

N#CCC(=O)C1CNCCO1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSC P53634 10/20 0.40
SSTR4 P31391 4/20 0.38
KCNH2 Q12809 1/20 0.36
REN P00797 6/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11244759 0.98 CTSC (0.39) CTSCSSTR4KCNH2REN
SCHEMBL7310959 0.82 SSTR4 (0.42) CTSCSSTR4KCNH2REN
SCHEMBL295081 0.77 SSTR4 (0.44) CTSCSSTR4REN
SCHEMBL1194327 0.77 SSTR4 (0.41) CTSCSSTR4REN
SCHEMBL3364696 0.77 SSTR4 (0.41) CTSCSSTR4REN
SCHEMBL23230712 0.77 SSTR4 (0.44) CTSCSSTR4REN
SCHEMBL2688364 0.77 SSTR4 (0.41) CTSCSSTR4REN
SCHEMBL294851 0.77 SSTR4 (0.41) CTSCSSTR4REN
SCHEMBL15485217 0.74 NOS2 (0.41)
SCHEMBL9204612 0.74 SSTR4 (0.46) CTSCSSTR4REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102690280-B Chiral zinc nitrogen coordination compounds LUO MEI 2015-02-11 CN disclosed
CN-102690280-A Chiral zinc nitrogen coordination compounds MEI LUO 2012-09-26 CN disclosed
US-20090030197-A1 Quinoline Intermediates of Receptor Tyrosine Kinase Inhibitors and the Synthesis Thereof WYETH (US) 2009-01-29 US disclosed
US-7432377-B2 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof WYETH (US) 2008-10-07 US disclosed
EP-1711467-A2 QUINOLINE INTERMEDIATES OF RECEPTOR TYROSINE KINASE INHIBITORS AND THE SYNTHESIS THEREOF Wyeth (US) 2006-10-18 EP disclosed
WO-2005070890-A2 QUINOLINE INTERMEDIATES OF RECEPTOR TYROSINE KINASE INHIBITORS AND THE SYNTHESIS THEREOF WYETH (US) 2005-08-04 WO disclosed
US-20050159446-A1 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof WYETH 2005-07-21 US disclosed
EP-0008802-B1 ERGOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING THEM FARMITALIA CARLO ERBA S.p.A. (IT) 1982-07-21 EP disclosed
US-4321381-A Ergot derivatives FARMITALIA CARLO ERBA S.P.A. (IT) 1982-03-23 US disclosed
US-4252941-A HYPOTENSIVE AGENTS, ANTIPROLACTINIC AGENTS FARMITALIA CARLO ERBA S.P.A. (IT) 1981-02-24 US disclosed
EP-0008802-A1 Ergoline derivatives, their preparation and therapeutic composition containing them FARMITALIA CARLO ERBA S.p.A. (IT) 1980-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030197-A1 Quinoline Intermediates of Receptor Tyrosine Kinase Inhibitors and the Synthesis Thereof ABL1, RET, ERBB2 CTSC 2499/4885SSTR4 1118/4885KCNH2 1930/4885
US-20050159446-A1 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof ABL1, RET, ERBB2 CTSC 2499/4885SSTR4 1118/4885KCNH2 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.